Tip:
Highlight text to annotate it
X
>>>Dr. David A. Margileth: A triple negative breast cancer is defined as breast cancers
that have negative estrogen receptor, negative progesterone receptor and negative HER2/neu
gene. What that means is that we are left only with chemotherapy as a modality to decrease
systemic recurrence. In that, anti-estrogen drugs like aromatase inhibitors or Tamoxifen
and Herceptin for the HER2/neu gene would not be helpful in decreasing the chance of
recurrence of triple negative tumors.
They tend to be more aggressive. They tend to be more common in younger women and they
tend to be more common in younger women with what’s called ‘BRCA-1 gene abnormalities’.
The prognosis is a little worse than most cancers and for that reason one takes an aggressive
chemotherapy approach to decrease systemic recurrence and the prognosis is most importantly
determined by the lymph node status and secondarily the size of the tumor.
The higher the number of positive lymph nodes, the higher the long-term risk of recurrence
and obviously, the idea would be to have no positive lymph nodes. With a large number
of lymph nodes, unfortunately the prognosis is not great and with over ten positive lymph
nodes, the chance of systemic recurrence at some point is probably over 50 or 60%. With
negative nodes, the chance of recurrence after appropriate local and systemic therapies might
be 10 or 20%.
Hi, I am Dr. Jay Harness and I want to share with you an important information that I believe
that every newly diagnosed patient with breast cancer needs to know.
Susan Denver: I am a breast cancer survivor.
Katherine Stockton: I am a breast cancer survivor.
Coree: I am a breast cancer survivor.
Susan Denver: And I want every woman to know…
Katherine Stockton: …about personalized breast cancer treatment…
Susan Denver: …and the Genomic Test.
Coree: A test that helps guide a woman and her doctor…
Katherine Stockton: …to the best treatment options for her.
Susan Denver: Pass it on!